Wang, Shuyuan team published research in European Journal of Medicinal Chemistry in 2021 | 2905-24-0

2905-24-0, 3-Bromobenzenesulfonyl chloride is an aryl sulfonyl chloride derivative. It participates in the synthesis of N-sulfonylanthranilic acid derivatives and potent P1′ benzenesulfonyl azacyclic urea human immunodeficiency virus (HIV) protease inhibitors.
3-Bromobenzenesulfonyl chloride is a molecule that can be used to inhibit the uptake of 3-bromobenzoate. The inhibition of uptake is due to the desymmetrization of the unsymmetrical, 3-bromobenzoate. This reaction leads to an increase in the concentration of 3-bromobenzoate. Inhibition studies have shown that 3-bromobenzenesulfonyl chloride has an inhibitory effect on cancer cells and apoptosis pathway. The structural studies have shown that this drug is synthetic and biphenyl can be synthesized from it. T-cell lymphomas have been shown to be inhibited by this drug and heart disease has also been inhibited., COA of Formula: C6H4BrClO2S

Chlorinated organic compounds are found in nearly every class of biomolecules. 2905-24-0, formula is C6H4BrClO2S, Name is 3-Bromobenzenesulfonyl chloride. Alkyl chlorides, as versatile building blocks in organic chemistry, are used in the preparation of alcohols, thioethers, alkenes, alkynes, esters, and Grignard reagents. COA of Formula: C6H4BrClO2S.

Wang, Shuyuan;Xu, Yue;Zhao, Yan;Zhang, Shun;Li, Min;Li, Xiaowei;He, Jinzhao;Zhou, Hong;Ge, Zemei;Li, Runtao;Yang, Baoxue research published 《 N-(4-acetamidophenyl)-5-acetylfuran-2-carboxamide as a novel orally available diuretic that targets urea transporters with improved PD and PK properties》, the research content is summarized as follows. Urea transporters (UTs) have been identified as new targets for diuretics. Functional deletion of UTs led to urea-selective urinary concentrating defects with relative salt sparing. In our previous study, a UT inhibitor with a diarylamide scaffold, which is denoted as I, was demonstrated as the first orally available UT inhibitor. However, the oral bioavailability of I was only 4.38%, which obstructed its clin. application. In this work, by replacing the nitro group of I with an acetyl group, II was obtained. Compared with I, II showed a 10 times stronger inhibitory effect on UT-B (0.14μM vs. 1.41μM in rats, and 0.48μM vs. 5.82μM in mice) and a much higher inhibition rate on UT-A1. Moreover, the metabolic stability both in vitro and in vivo and the drug-like properties (permeability and solubility) of II were obviously improved compared with those of I. Moreover, the bioavailability of II was 15.18%, which was 3 times higher than that of I, thereby resulting in significant enhancement of the diuretic activities in rats and mice. II showed excellent potential for development as a promising clin. diuretic candidate for targeting UTs to treat diseases that require long-term usage of diuretics, such as hyponatremia.

2905-24-0, 3-Bromobenzenesulfonyl chloride is an aryl sulfonyl chloride derivative. It participates in the synthesis of N-sulfonylanthranilic acid derivatives and potent P1′ benzenesulfonyl azacyclic urea human immunodeficiency virus (HIV) protease inhibitors.
3-Bromobenzenesulfonyl chloride is a molecule that can be used to inhibit the uptake of 3-bromobenzoate. The inhibition of uptake is due to the desymmetrization of the unsymmetrical, 3-bromobenzoate. This reaction leads to an increase in the concentration of 3-bromobenzoate. Inhibition studies have shown that 3-bromobenzenesulfonyl chloride has an inhibitory effect on cancer cells and apoptosis pathway. The structural studies have shown that this drug is synthetic and biphenyl can be synthesized from it. T-cell lymphomas have been shown to be inhibited by this drug and heart disease has also been inhibited., COA of Formula: C6H4BrClO2S

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics